Ozempic’s Hidden Workplace Shock

A healthcare professional preparing a syringe from a vial — OZEMPIC WORKPLACE IMPACT

New research says the same weight-loss shots reshaping American waistlines may also be quietly shrinking long-term sick leave at work by about one-sixth.

Story Snapshot

Economic study of Danish workers links GLP-1 drugs to a 17.3% drop in long-term sick leave
Researchers estimate annual savings equal to about 1.3% to 1.5% of a worker’s income
Better health from these drugs may reduce hospital visits and long sickness spells, not just body weight
Employers now face a hard question: are high drug costs worth fewer absences and stronger productivity?

Weight-loss shots step into the workplace

Glucagon-like peptide-1 medicines, better known by brand names like Ozempic and Wegovy, started as tools to manage diabetes and help people lose weight. Over the last few years, they turned into a cultural flashpoint, with politics, body image, and health policy all colliding.

Now a new front is opening: the labor market. A National Bureau of Economic Research working paper finds that workers who start GLP-1 treatment take noticeably fewer long sickness leaves than similar workers who do not.

GLP-1 drugs linked to 17% drop in worker sick leave, new economic study finds. https://t.co/h3Jjwf2KAI

— CBS News (@CBSNews) July 22, 2026

The study uses detailed national health and employment records from Denmark to track adults who begin GLP-1 therapy and compares them with patients who start the same drugs four years later. That “future user” design tries to line up people with similar health profiles and motivation while focusing on when they start the medicine.

Long-term sick leave is defined very clearly: medically certified absence from work lasting more than 30 days. That matters for employers because these spells usually trigger disability rules, higher costs, and staffing headaches.

What the 17.3 percent drop really means

The headline number is simple but powerful. After GLP-1 initiation, workers see a 0.95 percentage point decline in long-term sickness leave over four years, which equals a 17.3% drop compared with their pre-treatment average of 5.5%.

The effect grows over time, from about 0.8 percentage points in the first two years to roughly 1.1 percentage points in years three and four. That pattern fits with the idea that as weight, blood sugar, and related conditions improve, health stabilizes, and long absences become less frequent.

Researchers do not stop at percentages. They translate the change into money. Fewer long sickness spells and lower health care use add up to an estimated fiscal benefit of about 1.3% to 1.5% of annual labor income per treated worker. In dollar terms, they peg combined employer and public savings at roughly 866 dollars per employed individual each year.

For a large company with thousands of covered workers, that moves quickly into real budget territory. For taxpayers in systems with public sick leave and disability funds, it hints at relief rather than new strain.

Why better health shows up as fewer sick days

GLP-1 drugs do more than flatten the number on the bathroom scale. Medical trials and reviews show they cut risks for heart attacks, strokes, kidney disease, sleep apnea, and other chronic problems that often push people out of work or into repeated hospital stays.

In the Danish labor paper, patients on GLP-1 therapy also had fewer emergency department visits, lower use of cardiovascular medicines, and reduced reliance on long-term sickness benefits. When you connect those dots, the sick-leave findings look like a downstream effect of broad health gains.

Workplace health research has long found that productivity losses from illness often exceed direct medical and pharmacy costs by more than two to one. Chronic conditions such as obesity, depression, and back pain drive much of that drag.

A treatment that lightens that burden even modestly can create outsized economic value. That is the conservative business case here: healthy workers show up more, stay off long-term disability, and depend less on government programs.

The catch: high costs, side effects, and policy choices

None of this means GLP-1 drugs are a magic switch for the workforce. These injections are expensive, often running thousands of dollars per patient per year.

Many employer health plans still refuse to cover them for weight loss and only do so for diabetes treatment, and no federal law yet forces coverage for either use.

One state, North Dakota, has moved to require coverage for some plans starting in 2025, but that rule does not touch large employer plans that cover most workers. Companies still have broad freedom to say “yes” or “no.”

Side effects also matter. Common problems include nausea, vomiting, diarrhea, constipation, and abdominal pain, along with fatigue and headaches. More serious but less frequent risks involve the pancreas, kidneys, gallbladder, or thyroid. In countries with statutory sick pay, even time off due to drug side effects can qualify for paid leave.

So if employers and insurers push GLP-1 use too aggressively, they might swap one kind of sick day for another. Responsible coverage means targeting patients who truly need the medicine and pairing it with proper medical oversight.

What this means for employers and public policy

For employers who value work ethic, personal responsibility, and limited government dependency, the study offers an intriguing path. Covering GLP-1 drugs for the right workers may reduce long-term sick leave, lighten demands on public disability programs, and keep more people in the productive economy.

At the same time, the research is observational. It shows a strong association between GLP-1 treatment and lower sick leave, not a guaranteed causal outcome for every company or every worker. Prudent leaders will treat it as serious evidence, not a blank check.

GLP-1 drugs linked to 17% drop in worker sick leave, new economic study finds. https://t.co/h3Jjwf2KAI

— CBS News (@CBSNews) July 22, 2026

The broader lesson is bigger than one drug class. When medical care tackles chronic disease effectively, workplace productivity often improves, sometimes dramatically. GLP-1 medicines sit at the center of that story today because their effects are large, visible, and politically charged.